effects. The company’s work emphasizes overcoming limitations of traditional drug discovery by accelerating the identification and synthesis of compounds that can address resistance and unmet clinical needs. Its research pipeline includes therapeutics targeting bacterial, fungal, and viral infections as well as oncology indications, with candidates progressing through preclinical development. Stoked Bio also advances specific programs such as novel antibiotics discovered through AI-assisted methods, aiming to improve treatment options while reducing development time and cost.